Radiotherapy & Oncology
Volume 96, Issue 3 , Pages 335-338 , September 2010

PET scans in radiotherapy planning of lung cancer

  • Dirk De Ruysscher

      Affiliations

    • Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Center, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Maastricht University Medical Center, Department of Radiation Oncology (MAASTRO Clinic), GROW Research Institute, Maastricht, The Netherlands.
    • ,
  • Carl-Martin Kirsch

      Affiliations

    • Department of Nuclear Medicine, Saarland University Medical Center, Homburg, Germany

Received 4 June 2010 ,Revised 7 July 2010 ,Accepted 7 July 2010.

References 

  1. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–2333
  2. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48:59–69
  3. Dooms C, Verbeken E, Stroobants S, et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol. 2008;26:1128–1134
  4. Senan S, De Ruysscher D, Giraud P, et al. Literature-based recommendations for treatment planning and execution for high-precision radiotherapy in lung cancer. Radiother Oncol. 2004;71:139–146
  5. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81:209–225
  6. Nestle U, Schaefer-Schuler A, Kremp S, et al. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:453–462
  7. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET-CT planning in patients with clinical CT stage N2/N3 M0 non-small cell lung cancer (NSCLC): a modelling study. Int J Radiat Oncol Biol Phys. 2005;61:648–654
  8. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: results of a prospective study. Radiother Oncol. 2005;77:5–10
  9. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation on basis of the FDG-PET scan in patients with non-small cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2005;62:988–994
  10. Belderbos JS, Heemsbergen WD, De Jaeger K, et al. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  11. Sura S, Greco C, Gelblum D, et al. (18)F-Fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1397–1402
  12. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342–1348
  13. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–778
  14. Stroom J, Blaauwgeers H, van Baardwijk A, et al. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys. 2007;69:267–275
  15. Schaefer A, Kremp S, Hellwig D, et al. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35:1989–1999
  16. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol. 2009;91:85–94
  17. Nehmeh SA, Erdi YE, Rosenzweig KE, et al. Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. J Nucl Med. 2003;44:1644–1648
  18. Grgic A, Nestle U, Schaefer-Schuler A, et al. FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning – an intraindividual comparison. Int J Radiat Oncol Biol Phys. 2009;73:103–111
  19. Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–1604
  20. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287–293
  21. van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stage I–III non-small cell lung cancer. J Clin Oncol. 2010;28:1380–1386
  22. Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of (18)F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys. 2008;71:1402–1407
  23. Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–392
  24. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy in relation to metabolic response. A prospective study in locally advanced non-small cell lung cancer patients. Radiother Oncol. 2007;82:145–152
  25. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614–1620
  26. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–345
  27. Niho S, Fujii H, Murakami K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer. 2007;57:328–333
  28. Pandit N, Gonen M, Krug L, et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78–84
  29. Shen YY, Shiau YC, Wang JJ, et al. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res. 2002;22:1257–1264
  30. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003;44:1911–1917
  31. van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of 18FDG-PET scans in limited disease small cell lung cancer: a phase II trial. Int J Radiat Oncol Biol Phys. 2010;77:329–336
  32. van Loon J, Offermann C, Bosmans G, et al. (18)FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol. 2008;87:49–54
  33. Mees G, Dierckx R, Vangestel C, et al. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging. 2009;36:1674–1686
  34. Christian N, Lee JA, Bol A, et al. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol. 2009;91:101–106
  35. Lohith TG, Kudo T, Demura Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948–1953
  36. van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008;14:3326–3339
  37. Everitt S, Hicks RJ, Ball D, et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial (18)F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:1098–1104
  38. Nestle U, Weber W, Hentschel M, et al. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol. 2009;54:R1–R25
  39. Ollers M, Bosmans G, van Baardwijk A, et al. The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. Radiother Oncol. 2008;87:142–146

☆ Guidelines for the use of PET in radiotherapy planning A. Chiti (EANM) and V. Grégoire (ESTRO).

PII: S0167-8140(10)00385-3

doi: 10.1016/j.radonc.2010.07.002

Radiotherapy & Oncology
Volume 96, Issue 3 , Pages 335-338 , September 2010

Article Tools

* Image Usage & Resolution